The fast track approval route has been mentioned by the company several times. So I agree this is a goal. I see some of the funds from the CR are to be used to run an expansion trial off the phase 1 results. This will be to gain more data to support fast track approval.
So I think the timeline for the phase 2b/3 trial will be strechted a bit beyound 2023.
Another company i am invested in has just attempted to raise $36 million to run a fast track approval trial. That trial will last 12 months with 108 patients. As an example.
valuation thoughts, page-202
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.2¢ |
Change
0.002(20.0%) |
Mkt cap ! $11.70M | |||
| Open | High | Low | Value | Volume |
| 1.0¢ | 1.3¢ | 1.0¢ | $153.9K | 13.87M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 128195 | 1.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.2¢ | 1224999 | 4 |
View Market Depth
| Last trade - 16.10pm 05/11/2024 (20 minute delay) ? |
| CHM (ASX) Chart |